Spring 2025 Newsletter

Easton Center's Spring 2024 Newsletter highlights Dr. Sánchez López's answers to FAQs about lecanemab and ELHA Lab, bridging science to LA County's Latino communities.
By Jessica Vrazilek, Jessica Rexach, MD, PhD, and The Drug Discovery Lab
1 min read

 

In This Issue:

  • Advancing Hope Through Philanthropy
  • Bridging Genetics and Alzheimer’s: Unlocking the Role of APOE4 with the Support of Donors
  • Targeting the Major Risk Factor for Alzheimer’s Disease, Apolipoprotein E4 By SE-CRISPR Gene Editing in the Brain
  • Clinical Trials
  • Upcoming Events

The Mary S. Easton Center for Alzheimer’s Research and Care at UCLA has very active teams working on basic research, drug discovery, biomarkers for early diagnosis and clinical activity including clinical trials, cognitive testing, and patient care.

Advancing Hope Through Philanthropy

Advancing Hope Through Philanthropy image of a couple holding hands.

 

At the Mary S. Easton Center for Alzheimer's Research and Care at UCLA, advancing hope isn’t just a phrase—it’s a shared mission. In an era of growing challenges to public research funding, philanthropy has become more than supportive; it’s essential. The generosity of our donor community is fueling the breakthroughs that bring renewed hope to individuals and families facing Alzheimer’s disease— and sustaining our efforts to deliver care, discovery, and compassion at every step.

Pioneering Research Amidst Funding Challenges

The Easton Center remains at the forefront of Alzheimer's research, focusing on early diagnosis and the development of new therapeutic agents. Our multidisciplinary approach encompasses basic science studies, animal models, biomarker research, and clinical trials of novel medications. Despite the broader financial challenges impacting research institutions nationwide, our commitment to advancing the understanding and treatment of Alzheimer's disease remains unwavering.

Recent Milestones and Collaborative Efforts

In 2024, the Easton Center achieved significant milestones, including the launch of the UCLA Amyloid Immunotherapy Care (AIC) Program. This initiative has enabled the treatment of patients with groundbreaking therapies such as lecanemab and donanemab, marking a new era in Alzheimer's care. Our collaborative efforts with other UC Health campuses have established shared clinical guidelines, ensuring the safe and responsible use of these treatments.

Continue reading the article.